DRUG
Ziconotide 100 MCG(microgram)/ML Intrathecal Solution
Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.
Status
Completed
Phase
Phase 4
Enrollment
13
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The primary objective of this study is to prospectively examine outcomes in 12 patients using ziconotide Intrathecal Drug Therapy(IDT) as first-line monotherapy with the use of an algorithm of slow titration for dosing. The use of Prialt has demonstrated fewer and less serious associated adverse effects as compared to IDT morphine, especially when titrated slowly. We will use an average Numerical Rating Scale as our primary outcome and the Oswestry Disability Index(ODI), Beck Depression Inventory (BDI), Pain Catastrophizing Scale (PCS), Clinical Global Impression of Change Scale including binary satisfaction measures(CGIC), Lawton-Brody Instrumental Activities of Daily Living(IADL) and Short Form-36 as secondary outcome measures.
Interventions
Treatment arms and agents.
DIAGNOSTIC_TEST
Quantitative sensory testing
Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
DIAGNOSTIC_TEST
Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor
Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
Timeline
From registration to results.
First posted
Oct 26, 2017
Study start
Nov 3, 2016
Primary completion
Aug 30, 2020
Study completion
Dec 30, 2020
Results posted
Not reported
Registry updated
Jan 12, 2021
Outcomes
What the study measures.
Primary outcomes
Numerical Rating Scale (NRS)
Time frame · Baseline, 3, 4, 6, 8, 9, 10, 12 week and 4, 5, 6 and 12 months
This scale allows the subject to quantify their pain numerically, with 10 being the worst pain imaginable. This scale describe subject reported pain at its worst and best in the week prior to reporting, as well as total pain on average, and at the time of documentation. The mean of these scores will be used as the primary outcome. This scale also includes a question of subject experienced global improvement in which the patient is asked to quantify their overall change in pain with 0 being no change and 10 being completely changed. Using the NRS we will calculate a responder rate, assessing percentage of patients with a 50% response in NRS
Secondary outcomes
Oswestry Disability Index Scale
Time frame · Baseline, 12 weeks, 6 month, 12 month
Comprises 11 sections, this survey asks the patient to indicate the degree to which they have difficulty in daily life relating to pain.
SF (Short Form) - 36
Time frame · Baseline, 12 weeks, 6 month
This scale utilizes 36 questions to determine overall quality of life in patients by discussing physical health, emotional health, and social engagement.
IADL(Instrumental Activities of Daily Living)
Time frame · Baseline, 12 weeks, 6 month, 12 month
Used to assess complex functional activities of daily living, this scale extrapolates on basic activities such as ability to eat or walk, to include cooking shopping, housekeeping.
Beck Depression Inventory
Time frame · Baseline, 12 weeks, 6 month, 12 month
21 question survey pertaining to a patient's severity of depression. Each question is scored for 0 to 3, with 0 indicating no depression and 3 indicating the most severe depression
Pain Catastrophizing Scale
Time frame · Baseline, 12 weeks, 6 month, 12 month
This scale separates three types of catastrophizing: rumination, magnification and helplessness. Catastrophic thinking can contribute to the probability that a pain condition will be persistent over tim.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: 1. Must be eligible for implantation of an intrathecal analgesia programmable pump system using ziconotide IT. 2. Must be 18 years of age or older for all points of data collection. 3. Must be diagnosed with neuropathic pain secondary to a clear etiology. Acceptable etiologies including but not limited to diabetic neuropathy, small fiber neuropathy, and post herpetic neuropathy. Exclusion Criteria: 1. Must not have or been previously implanted with a programmable pump system. 2. Untreated mental illness including depression or anxiety determined by preoperative psychological evaluation. 3. Active substance abuse determined by preoperative urine drug screen. 4. Unwillingness to decrease oral medications at screening. 5. Any prior use of intrathecal analgesia besides trialing
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Albany Medical College
Albany, New York, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Ziconotide.
NCT IDStudyPhase / statusEnrollmentUpdated
Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer
Clinique Bizet · Pancreatic Cancer Pain · Intrathecal Analgesic
Not applicable
Not yet recruiting
40
2026-07
Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy
Christian Hospital Northeast Northwest · Chemotherapy Induced Peripheral Neuropathy (CIPN)
Not applicable
Not yet recruiting
24
2026-03
OP2C : Prialt® Observatory in Clinical Practice
Institut Cancerologie de l'Ouest · Refractory Pain
Not applicable
Recruiting
300
2025-08
Ziconotide for Non-cancer Pain by Intrathecal Administration
ESTEVE Pharmaceuticals SAS · Pain, Chronic
Not applicable
Recruiting
85
2025-02
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
National Cancer Institute, Naples · Pain · Neuropathic Pain
Phase 2
Unknown
16
2023-03
Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic
Hospices Civils de Lyon · Severe Refractory Neuropathic Pain · Spinal Cord Lesions
Phase 3
Unknown
44
2019-05
Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
Eisai Limited · Pain Management · Severe Chronic Pain
Not applicable
Completed
219
2018-10
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
Aaron Boster · Painful Myelopathy · Painful Neuropathy
Phase 4
Withdrawn
0
2018-09
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.